Navigation Links
New drug target for Alzheimer's, stroke is discovered by University at Buffalo scientists
Date:10/11/2011

BUFFALO, N.Y. -- A tiny piece of a critical receptor that fuels the brain and without which sentient beings cannot live has been discovered by University at Buffalo scientists as a promising new drug target for Alzheimer's and other neurodegenerative diseases.

The research on the NMDA (N-methyl-D-aspartate) receptor is being published online Oct. 11 in Nature Communications.

"This is the first time that this site has been shown to be useful as a drug target," says Gabriela K. Popescu, PhD, associate professor of biochemistry in UB's School of Medicine and Biomedical Sciences and senior author on the study.

"If we could find a drug that attaches itself to this site and locks together NMDA receptor subunits, that would be huge for fighting disability from stroke and Alzheimer's and other neurodegenerative diseases."

The research focuses on the brain's receptors for the neurotransmitter, glutamate, which is implicated in these diseases as well as in other conditions, such as glaucoma.

The two main glutamate receptors in the brain are NMDA and AMPA receptors, both of which play critical roles in human learning and memory. Both types of receptors are made of four subunits and within each receptor these subunits are organized in pairs called dimers.

Because these receptors are so similar in structure, Popescu explains, it was assumed that they function in much the same way.

"But when we altered the dimer interface, the site where two subunits come together within each pair, we found that the NMDA receptor works just the opposite of the way that the AMPA receptor works," Popescu explains. "Cementing this interface in AMPA receptors leads to more activity, whereas we found just the opposite to be true in NMDA receptors."

By locking the subunits together, the UB researchers were able to achieve a marked reduction in NMDA activity and, subsequently, a marked reduction in the amount of calcium that enters neurons in response to
'/>"/>

Contact: Ellen Goldbaum
goldbaum@buffalo.edu
716-645-4605
University at Buffalo
Source:Eurekalert

Page: 1 2

Related biology news :

1. Cleveland Clinic study discovers new targets for treating inflammatory, autoimmune diseases
2. Better planning required if EU is to meet energy targets
3. Targeting HIVs sugar coating
4. Protein found in heart may be target for colon cancer therapies
5. International study identifies new gene targets for hypertension treatment
6. Gladstone scientist finds new target for treating symptoms of Parkinsons disease
7. Researchers publish study on neuronal RNA targeting
8. A jumping genes preferred targets may influence genome evolution
9. Researchers identify new drug target that stimulates
10. Research offers new way to target shape-shifting proteins
11. Government-led efforts targeting eating habits of children needed to curb worldwide obesity epidemic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... Orleans, LA After studying noise in one French ... not noise levels exceeded municipal ordinances, Annette Hurley, PhD, ... New Orleans, and Eric Arriaga, a third-year LSUHSC doctor ... to protect their own hearing health. Their case study ... Advance for Hearing Practice Management ., "An important part ...
(Date:5/23/2013)... , Automated conserved noncoding sequence ... evolution among grasses , Within the genome of ... that undergo little change in position and sequence over ... proteins. Some of these evolutionarily stable sequences, so-called conserved ... of other genes or the condensation of chromosomes, but ...
(Date:5/23/2013)... More than 13,000 ships per year, carrying more than 284 ... generating roughly $1.8 billion dollars in toll fees for the ... than 55 million gallons of water are used from Gatun ... 2 million people living in the isthmus. , However, ... than 20 percent of the ships at sea, has demanded ...
Breaking Biology News(10 mins):Please do try this at home 2Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3Reforestation study shows trade-offs between water, carbon and timber 2Reforestation study shows trade-offs between water, carbon and timber 3
... Society for Microbiology (ASM) BD Award for Research ... Stephen Dumler, M.D., Professor, The Johns Hopkins University ... Diagnostic Systems, this award recognizes a distinguished scientist ... important applications in clinical microbiology. Dumler,s most ...
... release is available in German . ... epoch, around 115,000 years ago, there were significant climate ... from the Eemian Interglacial to the Weichselian Glacial was ... possibly at least two warming events. This is the ...
... caused more than $193 million in hospital-based medical care ... problems such as asthma and pneumonia that are triggered ... Corporation study. Researchers estimate that exposure to excessive ... emergency room visits and hospital admissions over the study ...
Cached Biology News:American Society for Microbiology honors J. Stephen Dumler 2Were short warm periods typical for transitions between interglacial and glacial epochs? 2Study finds dirty air in California causes millions worth of medical care each year 2Study finds dirty air in California causes millions worth of medical care each year 3
(Date:5/23/2013)... 23, 2013 PuraMed BioScience ® , ... of over-the-counter (OTC) medicinal and healthcare products, announced ... the company based on low market capitalization valuation. ... All Natural Product to Treat Migraine Headaches ... Prescription Competitor , Currently Available Nationwide at ...
(Date:5/23/2013)... PI’s new LPS-24 positioners are ... mm travel range with closed-loop sensor resolution up ... these new positioners the ideal choice for high ... version is also available. , More Information: ... be found at: , http://www.physikinstrumente.com/en/products/prdetail.php?sortnr=1000745&prw-lps24 , ...
(Date:5/23/2013)... PARK, Calif. , May 23, 2013 ... oral treatment for pain has reached an important milestone, ... trial of VBY-036 - a selective cathepsin S inhibitor. ... VBY-036 is a double-blind, randomized, placebo-controlled study designed to ... doses of VBY-036 in healthy adults. "The ...
(Date:5/23/2013)... , May 23, 2013 Z Trim ... value-added ingredients to a variety of industries, announced that ... a panel discussion at this year,s National Restaurant Association ... 2013, on behalf of the Research Chefs Association.  Chef ... Restaurants: The Good, the Bad and the Ugly," joining ...
Breaking Biology Technology:PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Precision Positioning System Uses Miniaturezed Piezo Linear Motor: LPS-24 Linear Stage by PI 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 2Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 3
... of ... Directors, ... its platform technology to identify and,develop compounds that promote the growth ... announced today that it has,completed a $30 million initial closing of ...
... N.J., March 10 Palatin,Technologies, Inc. (Amex: ... Phase I,clinical trial of PL-3994, a novel, long-acting ... treatment of acute,decompensated congestive heart failure (CHF). The ... single ascending dose study,in 26 healthy volunteers who ...
... leader in,developing automated molecular testing solutions, announced today ... biotechnology companies presenting,at the 28th Annual Cowen Health ... Marriott Copley Place in Boston, Massachusetts. Fareed Kureshy,President ... of the,company, its automated molecular testing platform and ...
Cached Biology Technology:BrainCells Inc. Completes $30 Million Initial Closing of Series B Financing 2Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure 2Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure 3Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure 4
TNR-R2...
Complement C1q subcomponent subunit C precursor. [Source:Uniprot/SWISSPROT;Acc:P02747] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Sheep polyclonal to Melatonin ( Abpromise for all tested applications). Antigen: Melatonin Tg conjugate....
Goat anti-PITPN Class: Antibody Product Group: Miscellaneous Antibody...
Biology Products: